APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oncolytic Virus Therapy

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Selected research

Market Analysis & Forecast

Global Oncolytic Virus Therapy Market Analysis and Forecast 2026-2032

26 December 2025198 pages

Choose your research edition.

Industry ResearchOncolytic Virus Therapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Oncolytic Virus Therapy Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Oncolytic Virus Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oncolytic Virus Therapy Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Oncolytic Virus Therapy Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Oncolytic Virus Therapy is an exciting, increasingly recognized discipline in cancer research. Although the connection between viruses and cancer regression was recognized in the early 20th century, it wasn’t until the recent development of advanced genetic engineering techniques that true progress has been made using virotherapy to attack and destroy cancer cells. Today, researchers can modify existing viruses to create new oncolytic viruses that are less susceptible to immune suppression while more specifically targeting particular classes of cancer cells. Additionally, these modified oncolytic viruses can be adapted to insert and express cancer-suppressing genes and diagnostic proteins.

Amgen, Colytics Biotech, Iralytics and Ransgene SA are the leading providers of oncolytic virus therapy, with the first 3 accounting for about 60% of the market.

North America and Europe are the main markets, each accounting for about 40% of the market.

Read the full market overview

Report Includes

This report presents an overview of global market for Oncolytic Virus Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oncolytic Virus Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Oncolytic Virus Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oncolytic Virus Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oncolytic Virus Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oncolytic Virus Therapy revenue, projected growth trends, production technology, application and end-user industry.

Oncolytic Virus Therapy Segment by Company

Amgen

Oncolytics Biotech

Viralytics

Transgene SA

Oncolys BioPharma

Targovax

PsiOxus Therapeutics

SillaJen Biotherapeutics

Sorrento Therapeutics

Lokon Pharma

Genelux Corporation

Vyriad

TILT Biotherapeutics

Cold Genesys

Oncolytic Virus Therapy Segment by Type

HSV-based Oncolytic Viruses

Adenoviruses-based Oncolytic Viruses

Vaccinia Virus-based Oncolytic Viruses

Vesicular Stomatitis Virus-based Oncolytic Viruses

Newcastle Disease Virus-based Oncolytic Viruses

Oncolytic Virus Therapy Segment by Application

Melanoma

Prostate Cancer

Breast Cancer

Ovarian Cancer

Others

Oncolytic Virus Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncolytic Virus Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oncolytic Virus Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncolytic Virus Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oncolytic Virus Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oncolytic Virus Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncolytic Virus Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oncolytic Virus Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. HSV-based Oncolytic Viruses Major Player Table 3. Adenoviruses-based Oncolytic Viruses Major Player Table 4. Vaccinia Virus-based Oncolytic Viruses Major Player Table 5. Vesicular Stomatitis Virus-based Oncolytic Viruses Major Player Table 6. Newcastle Disease Virus-based Oncolytic Viruses Major Player Table 7. Global Oncolytic Virus Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Melanoma Major Player Table 9. Prostate Cancer Major Player Table 10. Breast Cancer Major Player Table 11. Ovarian Cancer Major Player Table 12. Others Major Player Table 13. Oncolytic Virus Therapy Industry Trends Table 14. Oncolytic Virus Therapy Industry Drivers Table 15. Oncolytic Virus Therapy Industry Opportunities and Challenges Table 16. Oncolytic Virus Therapy Industry Restraints Table 17. Global Oncolytic Virus Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Oncolytic Virus Therapy Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Oncolytic Virus Therapy Market Share by Region (2021-2026) Table 20. Global Oncolytic Virus Therapy Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Oncolytic Virus Therapy Market Share by Region (2027-2032) Table 22. Global Oncolytic Virus Therapy Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Oncolytic Virus Therapy Revenue Market Share by Players (2021-2026) Table 24. Global Oncolytic Virus Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Oncolytic Virus Therapy Key Players Headquarters & Area Served Table 26. Global Oncolytic Virus Therapy Players, Product Type & Application Table 27. Global Oncolytic Virus Therapy Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Oncolytic Virus Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Oncolytic Virus Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Oncolytic Virus Therapy Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Oncolytic Virus Therapy Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Oncolytic Virus Therapy Revenue Market Share by Type (2021-2026) Table 34. Global Oncolytic Virus Therapy Revenue Market Share by Type (2027-2032) Table 35. Global Oncolytic Virus Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Oncolytic Virus Therapy Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Oncolytic Virus Therapy Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Oncolytic Virus Therapy Revenue Market Share by Application (2021-2026) Table 39. Global Oncolytic Virus Therapy Revenue Market Share by Application (2027-2032) Table 40. Amgen Company Information Table 41. Amgen Business Overview Table 42. Amgen Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Amgen Oncolytic Virus Therapy Product Portfolio Table 44. Amgen Recent Development Table 45. Oncolytics Biotech Company Information Table 46. Oncolytics Biotech Business Overview Table 47. Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio Table 49. Oncolytics Biotech Recent Development Table 50. Viralytics Company Information Table 51. Viralytics Business Overview Table 52. Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Viralytics Oncolytic Virus Therapy Product Portfolio Table 54. Viralytics Recent Development Table 55. Transgene SA Company Information Table 56. Transgene SA Business Overview Table 57. Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Transgene SA Oncolytic Virus Therapy Product Portfolio Table 59. Transgene SA Recent Development Table 60. Oncolys BioPharma Company Information Table 61. Oncolys BioPharma Business Overview Table 62. Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio Table 64. Oncolys BioPharma Recent Development Table 65. Targovax Company Information Table 66. Targovax Business Overview Table 67. Targovax Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Targovax Oncolytic Virus Therapy Product Portfolio Table 69. Targovax Recent Development Table 70. PsiOxus Therapeutics Company Information Table 71. PsiOxus Therapeutics Business Overview Table 72. PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio Table 74. PsiOxus Therapeutics Recent Development Table 75. SillaJen Biotherapeutics Company Information Table 76. SillaJen Biotherapeutics Business Overview Table 77. SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio Table 79. SillaJen Biotherapeutics Recent Development Table 80. Sorrento Therapeutics Company Information Table 81. Sorrento Therapeutics Business Overview Table 82. Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio Table 84. Sorrento Therapeutics Recent Development Table 85. Lokon Pharma Company Information Table 86. Lokon Pharma Business Overview Table 87. Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Lokon Pharma Oncolytic Virus Therapy Product Portfolio Table 89. Lokon Pharma Recent Development Table 90. Genelux Corporation Company Information Table 91. Genelux Corporation Business Overview Table 92. Genelux Corporation Oncolytic Virus Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Genelux Corporation Oncolytic Virus Therapy Product Portfolio Table 94. Genelux Corporation Recent Development Table 95. Vyriad Company Information Table 96. Vyriad Business Overview Table 97. Vyriad Oncolytic Virus Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. Vyriad Oncolytic Virus Therapy Product Portfolio Table 99. Vyriad Recent Development Table 100. TILT Biotherapeutics Company Information Table 101. TILT Biotherapeutics Business Overview Table 102. TILT Biotherapeutics Oncolytic Virus Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 103. TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio Table 104. TILT Biotherapeutics Recent Development Table 105. Cold Genesys Company Information Table 106. Cold Genesys Business Overview Table 107. Cold Genesys Oncolytic Virus Therapy Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 108. Cold Genesys Oncolytic Virus Therapy Product Portfolio Table 109. Cold Genesys Recent Development Table 110. North America Oncolytic Virus Therapy Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Oncolytic Virus Therapy Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Oncolytic Virus Therapy Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Oncolytic Virus Therapy Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Oncolytic Virus Therapy Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Oncolytic Virus Therapy Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Oncolytic Virus Therapy Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Oncolytic Virus Therapy Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Oncolytic Virus Therapy Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Oncolytic Virus Therapy Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Oncolytic Virus Therapy Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Oncolytic Virus Therapy Revenue by Country (US$ Million) & (2027-2032) Table 124. China Oncolytic Virus Therapy Revenue by Type (2021-2026) & (US$ Million) Table 125. China Oncolytic Virus Therapy Revenue by Type (2027-2032) & (US$ Million) Table 126. China Oncolytic Virus Therapy Revenue by Application (2021-2026) & (US$ Million) Table 127. China Oncolytic Virus Therapy Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Oncolytic Virus Therapy Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Oncolytic Virus Therapy Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Oncolytic Virus Therapy Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Oncolytic Virus Therapy Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Oncolytic Virus Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Oncolytic Virus Therapy Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Oncolytic Virus Therapy Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Oncolytic Virus Therapy Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Oncolytic Virus Therapy Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Oncolytic Virus Therapy Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Oncolytic Virus Therapy Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Oncolytic Virus Therapy Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Oncolytic Virus Therapy Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Oncolytic Virus Therapy Image Figure 2. Global Oncolytic Virus Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oncolytic Virus Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. HSV-based Oncolytic Viruses Image Figure 5. Adenoviruses-based Oncolytic Viruses Image Figure 6. Vaccinia Virus-based Oncolytic Viruses Image Figure 7. Vesicular Stomatitis Virus-based Oncolytic Viruses Image Figure 8. Newcastle Disease Virus-based Oncolytic Viruses Image Figure 9. Global Oncolytic Virus Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Oncolytic Virus Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 11. Melanoma Image Figure 12. Prostate Cancer Image Figure 13. Breast Cancer Image Figure 14. Ovarian Cancer Image Figure 15. Others Image Figure 16. Global Oncolytic Virus Therapy Market Size (US$ Million) & (2021-2032) Figure 17. Global Oncolytic Virus Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Oncolytic Virus Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Oncolytic Virus Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Oncolytic Virus Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oncolytic Virus Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Oncolytic Virus Therapy Revenue Market Share by Type (2021-2032) Figure 24. Global Oncolytic Virus Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Oncolytic Virus Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Oncolytic Virus Therapy Revenue Market Share by Application (2021-2032) Figure 27. North America Oncolytic Virus Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Oncolytic Virus Therapy Revenue Share by Type (2021-2032) Figure 29. North America Oncolytic Virus Therapy Revenue Share by Application (2021-2032) Figure 30. North America Oncolytic Virus Therapy Revenue Share by Country (2021-2032) Figure 31. United States Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Oncolytic Virus Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Oncolytic Virus Therapy Revenue Share by Type (2021-2032) Figure 36. Europe Oncolytic Virus Therapy Revenue Share by Application (2021-2032) Figure 37. Europe Oncolytic Virus Therapy Revenue Share by Country (2021-2032) Figure 38. Germany Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Oncolytic Virus Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Oncolytic Virus Therapy Revenue Share by Type (2021-2032) Figure 48. China Oncolytic Virus Therapy Revenue Share by Application (2021-2032) Figure 49. Asia Oncolytic Virus Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Oncolytic Virus Therapy Revenue Share by Type (2021-2032) Figure 51. Asia Oncolytic Virus Therapy Revenue Share by Application (2021-2032) Figure 52. Asia Oncolytic Virus Therapy Revenue Share by Region (2021-2032) Figure 53. Japan Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Oncolytic Virus Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Oncolytic Virus Therapy Revenue Share by Type (2021-2032) Figure 61. SAMEA Oncolytic Virus Therapy Revenue Share by Application (2021-2032) Figure 62. SAMEA Oncolytic Virus Therapy Revenue Share by Country (2021-2032) Figure 63. Brazil Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Oncolytic Virus Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • HSV-based Oncolytic Viruses
  • Adenoviruses-based Oncolytic Viruses
  • Vaccinia Virus-based Oncolytic Viruses
  • Vesicular Stomatitis Virus-based Oncolytic Viruses
  • Newcastle Disease Virus-based Oncolytic Viruses
Applications
  • Melanoma
  • Prostate Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Others
Companies covered
  • Amgen
  • Oncolytics Biotech
  • Viralytics
  • Transgene SA
  • Oncolys BioPharma
  • Targovax
  • PsiOxus Therapeutics
  • SillaJen Biotherapeutics
  • Sorrento Therapeutics
  • Lokon Pharma
  • Genelux Corporation
  • Vyriad
  • TILT Biotherapeutics
  • Cold Genesys

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oncolytic Virus Therapy Market by Type
  3. 1.2.1 Global Oncolytic Virus Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 HSV-based Oncolytic Viruses
  5. 1.2.3 Adenoviruses-based Oncolytic Viruses
  6. 1.2.4 Vaccinia Virus-based Oncolytic Viruses
  7. 1.2.5 Vesicular Stomatitis Virus-based Oncolytic Viruses
  8. 1.2.6 Newcastle Disease Virus-based Oncolytic Viruses
  9. 1.3 Oncolytic Virus Therapy Market by Application
  10. 1.3.1 Global Oncolytic Virus Therapy Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Melanoma
  12. 1.3.3 Prostate Cancer
  13. 1.3.4 Breast Cancer
  14. 1.3.5 Ovarian Cancer
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Oncolytic Virus Therapy Market Dynamics
  1. 2.1 Oncolytic Virus Therapy Industry Trends
  2. 2.2 Oncolytic Virus Therapy Industry Drivers
  3. 2.3 Oncolytic Virus Therapy Industry Opportunities and Challenges
  4. 2.4 Oncolytic Virus Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oncolytic Virus Therapy Market Perspective (2021-2032)
  2. 3.2 Global Oncolytic Virus Therapy Growth Trends by Region
  3. 3.2.1 Global Oncolytic Virus Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oncolytic Virus Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Oncolytic Virus Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oncolytic Virus Therapy Revenue by Players
  2. 4.1.1 Global Oncolytic Virus Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Oncolytic Virus Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oncolytic Virus Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oncolytic Virus Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oncolytic Virus Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Oncolytic Virus Therapy Players, Product Type & Application
  8. 4.5 Global Oncolytic Virus Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oncolytic Virus Therapy Market CR5 and HHI
  11. 4.6.3 2025 Oncolytic Virus Therapy Tier 1, Tier 2, and Tier 3
5 Oncolytic Virus Therapy Market Size by Type
  1. 5.1 Global Oncolytic Virus Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oncolytic Virus Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Oncolytic Virus Therapy Revenue Market Share by Type (2021-2032)
6 Oncolytic Virus Therapy Market Size by Application
  1. 6.1 Global Oncolytic Virus Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oncolytic Virus Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Oncolytic Virus Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Amgen
  2. 7.1.1 Amgen Company Information
  3. 7.1.2 Amgen Business Overview
  4. 7.1.3 Amgen Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Amgen Oncolytic Virus Therapy Product Portfolio
  6. 7.1.5 Amgen Recent Developments
  7. 7.2 Oncolytics Biotech
  8. 7.2.1 Oncolytics Biotech Company Information
  9. 7.2.2 Oncolytics Biotech Business Overview
  10. 7.2.3 Oncolytics Biotech Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Oncolytics Biotech Oncolytic Virus Therapy Product Portfolio
  12. 7.2.5 Oncolytics Biotech Recent Developments
  13. 7.3 Viralytics
  14. 7.3.1 Viralytics Company Information
  15. 7.3.2 Viralytics Business Overview
  16. 7.3.3 Viralytics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Viralytics Oncolytic Virus Therapy Product Portfolio
  18. 7.3.5 Viralytics Recent Developments
  19. 7.4 Transgene SA
  20. 7.4.1 Transgene SA Company Information
  21. 7.4.2 Transgene SA Business Overview
  22. 7.4.3 Transgene SA Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Transgene SA Oncolytic Virus Therapy Product Portfolio
  24. 7.4.5 Transgene SA Recent Developments
  25. 7.5 Oncolys BioPharma
  26. 7.5.1 Oncolys BioPharma Company Information
  27. 7.5.2 Oncolys BioPharma Business Overview
  28. 7.5.3 Oncolys BioPharma Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Oncolys BioPharma Oncolytic Virus Therapy Product Portfolio
  30. 7.5.5 Oncolys BioPharma Recent Developments
  31. 7.6 Targovax
  32. 7.6.1 Targovax Company Information
  33. 7.6.2 Targovax Business Overview
  34. 7.6.3 Targovax Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Targovax Oncolytic Virus Therapy Product Portfolio
  36. 7.6.5 Targovax Recent Developments
  37. 7.7 PsiOxus Therapeutics
  38. 7.7.1 PsiOxus Therapeutics Company Information
  39. 7.7.2 PsiOxus Therapeutics Business Overview
  40. 7.7.3 PsiOxus Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 PsiOxus Therapeutics Oncolytic Virus Therapy Product Portfolio
  42. 7.7.5 PsiOxus Therapeutics Recent Developments
  43. 7.8 SillaJen Biotherapeutics
  44. 7.8.1 SillaJen Biotherapeutics Company Information
  45. 7.8.2 SillaJen Biotherapeutics Business Overview
  46. 7.8.3 SillaJen Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 SillaJen Biotherapeutics Oncolytic Virus Therapy Product Portfolio
  48. 7.8.5 SillaJen Biotherapeutics Recent Developments
  49. 7.9 Sorrento Therapeutics
  50. 7.9.1 Sorrento Therapeutics Company Information
  51. 7.9.2 Sorrento Therapeutics Business Overview
  52. 7.9.3 Sorrento Therapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sorrento Therapeutics Oncolytic Virus Therapy Product Portfolio
  54. 7.9.5 Sorrento Therapeutics Recent Developments
  55. 7.10 Lokon Pharma
  56. 7.10.1 Lokon Pharma Company Information
  57. 7.10.2 Lokon Pharma Business Overview
  58. 7.10.3 Lokon Pharma Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Lokon Pharma Oncolytic Virus Therapy Product Portfolio
  60. 7.10.5 Lokon Pharma Recent Developments
  61. 7.11 Genelux Corporation
  62. 7.11.1 Genelux Corporation Company Information
  63. 7.11.2 Genelux Corporation Business Overview
  64. 7.11.3 Genelux Corporation Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Genelux Corporation Oncolytic Virus Therapy Product Portfolio
  66. 7.11.5 Genelux Corporation Recent Developments
  67. 7.12 Vyriad
  68. 7.12.1 Vyriad Company Information
  69. 7.12.2 Vyriad Business Overview
  70. 7.12.3 Vyriad Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Vyriad Oncolytic Virus Therapy Product Portfolio
  72. 7.12.5 Vyriad Recent Developments
  73. 7.13 TILT Biotherapeutics
  74. 7.13.1 TILT Biotherapeutics Company Information
  75. 7.13.2 TILT Biotherapeutics Business Overview
  76. 7.13.3 TILT Biotherapeutics Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 TILT Biotherapeutics Oncolytic Virus Therapy Product Portfolio
  78. 7.13.5 TILT Biotherapeutics Recent Developments
  79. 7.14 Cold Genesys
  80. 7.14.1 Cold Genesys Company Information
  81. 7.14.2 Cold Genesys Business Overview
  82. 7.14.3 Cold Genesys Oncolytic Virus Therapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Cold Genesys Oncolytic Virus Therapy Product Portfolio
  84. 7.14.5 Cold Genesys Recent Developments
8 North America
  1. 8.1 North America Oncolytic Virus Therapy Revenue (2021-2032)
  2. 8.2 North America Oncolytic Virus Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Oncolytic Virus Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Oncolytic Virus Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Oncolytic Virus Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Oncolytic Virus Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Oncolytic Virus Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Oncolytic Virus Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Oncolytic Virus Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Oncolytic Virus Therapy Revenue by Country
  11. 8.6.1 North America Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oncolytic Virus Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Oncolytic Virus Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oncolytic Virus Therapy Revenue (2021-2032)
  2. 9.2 Europe Oncolytic Virus Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oncolytic Virus Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oncolytic Virus Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Oncolytic Virus Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oncolytic Virus Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oncolytic Virus Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oncolytic Virus Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Oncolytic Virus Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oncolytic Virus Therapy Revenue by Country
  11. 9.6.1 Europe Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oncolytic Virus Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oncolytic Virus Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oncolytic Virus Therapy Revenue (2021-2032)
  2. 10.2 China Oncolytic Virus Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Oncolytic Virus Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Oncolytic Virus Therapy Revenue by Type (2027-2032)
  5. 10.3 China Oncolytic Virus Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Oncolytic Virus Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Oncolytic Virus Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Oncolytic Virus Therapy Revenue by Application (2027-2032)
  9. 10.5 China Oncolytic Virus Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oncolytic Virus Therapy Revenue (2021-2032)
  2. 11.2 Asia Oncolytic Virus Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oncolytic Virus Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oncolytic Virus Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Oncolytic Virus Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oncolytic Virus Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oncolytic Virus Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oncolytic Virus Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Oncolytic Virus Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oncolytic Virus Therapy Revenue by Country
  11. 11.6.1 Asia Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oncolytic Virus Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oncolytic Virus Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oncolytic Virus Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Oncolytic Virus Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oncolytic Virus Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oncolytic Virus Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oncolytic Virus Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oncolytic Virus Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oncolytic Virus Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oncolytic Virus Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oncolytic Virus Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oncolytic Virus Therapy Revenue by Country
  11. 12.6.1 SAMEA Oncolytic Virus Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oncolytic Virus Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oncolytic Virus Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst